79 related articles for article (PubMed ID: 16721809)
1. Transcriptional census of 36 microdissected colorectal cancers yields a gene signature to distinguish UICC II and III.
Groene J; Mansmann U; Meister R; Staub E; Roepcke S; Heinze M; Klaman I; Brümmendorf T; Hermann K; Loddenkemper C; Pilarsky C; Mann B; Adams HP; Buhr HJ; Rosenthal A
Int J Cancer; 2006 Oct; 119(8):1829-36. PubMed ID: 16721809
[TBL] [Abstract][Full Text] [Related]
2. Molecular signature for lymphatic metastasis in colorectal carcinomas.
Croner RS; Förtsch T; Brückl WM; Rödel F; Rödel C; Papadopoulos T; Brabletz T; Kirchner T; Sachs M; Behrens J; Klein-Hitpass L; Stürzl M; Hohenberger W; Lausen B
Ann Surg; 2008 May; 247(5):803-10. PubMed ID: 18438117
[TBL] [Abstract][Full Text] [Related]
3. ColoGuideEx: a robust gene classifier specific for stage II colorectal cancer prognosis.
Agesen TH; Sveen A; Merok MA; Lind GE; Nesbakken A; Skotheim RI; Lothe RA
Gut; 2012 Nov; 61(11):1560-7. PubMed ID: 22213796
[TBL] [Abstract][Full Text] [Related]
4. Altered expression level of Sigma1 receptor gene in human colorectal cancer.
Skrzycki M; Czeczot H
J Recept Signal Transduct Res; 2013 Oct; 33(5):313-8. PubMed ID: 23906352
[TBL] [Abstract][Full Text] [Related]
5. MUC12 mRNA expression is an independent marker of prognosis in stage II and stage III colorectal cancer.
Matsuyama T; Ishikawa T; Mogushi K; Yoshida T; Iida S; Uetake H; Mizushima H; Tanaka H; Sugihara K
Int J Cancer; 2010 Nov; 127(10):2292-9. PubMed ID: 20162577
[TBL] [Abstract][Full Text] [Related]
6. MicroRNA‑133b inhibits connective tissue growth factor in colorectal cancer and correlates with the clinical stage of the disease.
Guo Y; Li X; Lin C; Zhang Y; Hu G; Zhou J; Du J; Gao K; Gan Y; Deng H
Mol Med Rep; 2015 Apr; 11(4):2805-12. PubMed ID: 25501363
[TBL] [Abstract][Full Text] [Related]
7. A molecular signature for the prediction of recurrence in colorectal cancer.
Wang L; Shen X; Wang Z; Xiao X; Wei P; Wang Q; Ren F; Wang Y; Liu Z; Sheng W; Huang W; Zhou X; Du X
Mol Cancer; 2015 Feb; 14(1):22. PubMed ID: 25645394
[TBL] [Abstract][Full Text] [Related]
8. Down-regulated GAS1 expression correlates with recurrence in stage II and III colorectal cancer.
Jiang Z; Xu Y; Cai S
Hum Pathol; 2011 Mar; 42(3):361-8. PubMed ID: 21111449
[TBL] [Abstract][Full Text] [Related]
9. Heterogeneity of colorectal cancers and extraction of discriminator gene signatures for personalized prediction of prognosis.
Miyake M; Takemasa I; Matoba R; Tanino M; Niijima S; Ikeda M; Yamamoto H; Sekimoto M; Kuhara S; Okayama T; Monden M; Matsubara K; Mori M
Int J Oncol; 2011 Oct; 39(4):781-9. PubMed ID: 21701771
[TBL] [Abstract][Full Text] [Related]
10. Prognostic role of p53 messenger ribonucleic acid expression in patients after curative resection for stage I to III colorectal cancer: association with colon cancer stem cell markers.
Huh JW; Kim HR; Kim YJ
J Am Coll Surg; 2013 Jun; 216(6):1063-9. PubMed ID: 23571142
[TBL] [Abstract][Full Text] [Related]
11. Microarray versus conventional prediction of lymph node metastasis in colorectal carcinoma.
Croner RS; Peters A; Brueckl WM; Matzel KE; Klein-Hitpass L; Brabletz T; Papadopoulos T; Hohenberger W; Reingruber B; Lausen B
Cancer; 2005 Jul; 104(2):395-404. PubMed ID: 15952189
[TBL] [Abstract][Full Text] [Related]
12. Identification of gene signatures for invasive colorectal tumor cells.
Wiese AH; Auer J; Lassmann S; Nährig J; Rosenberg R; Höfler H; Rüger R; Werner M
Cancer Detect Prev; 2007; 31(4):282-95. PubMed ID: 17936523
[TBL] [Abstract][Full Text] [Related]
13. Gene expression signature to improve prognosis prediction of stage II and III colorectal cancer.
Salazar R; Roepman P; Capella G; Moreno V; Simon I; Dreezen C; Lopez-Doriga A; Santos C; Marijnen C; Westerga J; Bruin S; Kerr D; Kuppen P; van de Velde C; Morreau H; Van Velthuysen L; Glas AM; Van't Veer LJ; Tollenaar R
J Clin Oncol; 2011 Jan; 29(1):17-24. PubMed ID: 21098318
[TBL] [Abstract][Full Text] [Related]
14. Detection of lymphatic invasion in early stage primary colorectal cancer with the monoclonal antibody D2-40.
Walgenbach-Bruenagel G; Tolba RH; Varnai AD; Bollmann M; Hirner A; Walgenbach KJ
Eur Surg Res; 2006; 38(5):438-44. PubMed ID: 16912482
[TBL] [Abstract][Full Text] [Related]
15. Expression of annexin a5 is associated with higher tumor stage and poor prognosis in colorectal adenocarcinomas.
Xue G; Hao LQ; Ding FX; Mei Q; Huang JJ; Fu CG; Yan HL; Sun SH
J Clin Gastroenterol; 2009 Oct; 43(9):831-7. PubMed ID: 19461527
[TBL] [Abstract][Full Text] [Related]
16. Analysis of RGS2 expression and prognostic significance in stage II and III colorectal cancer.
Jiang Z; Wang Z; Xu Y; Wang B; Huang W; Cai S
Biosci Rep; 2010 Dec; 30(6):383-90. PubMed ID: 20001967
[TBL] [Abstract][Full Text] [Related]
17. Tropism between hepatic and pulmonary metastases in colorectal cancers.
Kim SH; Choi SJ; Park JS; Lee J; Cho YB; Kang MW; Lee WY; Choi YS; Kim HK; Han J; Chun HK; Kim J
Oncol Rep; 2012 Aug; 28(2):459-64. PubMed ID: 22664832
[TBL] [Abstract][Full Text] [Related]
18. A colorectal cancer expression profile that includes transforming growth factor beta inhibitor BAMBI predicts metastatic potential.
Fritzmann J; Morkel M; Besser D; Budczies J; Kosel F; Brembeck FH; Stein U; Fichtner I; Schlag PM; Birchmeier W
Gastroenterology; 2009 Jul; 137(1):165-75. PubMed ID: 19328798
[TBL] [Abstract][Full Text] [Related]
19. Prognostic markers in early-stage colorectal cancer: significance of TYMS mRNA expression.
Koumarianou A; Tzeveleki I; Mekras D; Eleftheraki AG; Bobos M; Wirtz R; Fountzilas E; Valavanis C; Xanthakis I; Kalogeras KT; Basdanis G; Pentheroudakis G; Kotoula V; Fountzilas G
Anticancer Res; 2014 Sep; 34(9):4949-62. PubMed ID: 25202077
[TBL] [Abstract][Full Text] [Related]
20. Prognostic significance of multiple molecular markers for patients with stage II colorectal cancer undergoing curative resection.
Uen YH; Lin SR; Wu DC; Su YC; Wu JY; Cheng TL; Chi CW; Wang JY
Ann Surg; 2007 Dec; 246(6):1040-6. PubMed ID: 18043108
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
